Please login to the form below

Not currently logged in
Email:
Password:

Michael Fleming joins biosimilars firm Coherus

He has experience at Elan, Genentech and GSK

Coherus Biosciences has named Michael Fleming as senior VP, commercial strategy.

Fleming was most recently at Elan where he was head of commercial and of the company's Tysabri (natalizumab) franchise.

He joins Coherus as it begins to advance its pipeline of biosimilars towards commercialisation, a process that has already seen it sign an alliance with Baxter to develop a biosimilar version of Amgen and Pfizer's big-selling arthritis and psoriasis drug Enbrel (etanercept).

“Michael's experience in building commercial operations and his knowledge of markets and health systems are of immediate importance,” said Danny Lanfear, CEO of Coherus.

“He will play a key role in defining strategies that effectively maximise the commercial potential of our products.”

Fleming gained experience in commercialising biological medicines during his time leading the strategy for Elan's multiple sclerosis drug Tysabri.

His other experience includes senior commercial roles at GlaxoSmithKline, Genentech, Nuvelo, Agendia and Campbell Alliance.

1st May 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics